208 related articles for article (PubMed ID: 32706893)
21. Anti-apoptotic pathways in bone marrow and megakaryocytes in myeloproliferative neoplasia.
Koopmans SM; Schouten HC; van Marion AM
Pathobiology; 2014; 81(2):60-8. PubMed ID: 24280934
[TBL] [Abstract][Full Text] [Related]
22. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.
Baumeister J; Chatain N; Sofias AM; Lammers T; Koschmieder S
Cells; 2021 Dec; 10(12):. PubMed ID: 34944059
[TBL] [Abstract][Full Text] [Related]
23. Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms.
Krečak I; Peran N; Lapić I; Gverić-Krečak V; Krečak F; Rončević P; Duraković N
Wien Klin Wochenschr; 2021 Jan; 133(1-2):62-64. PubMed ID: 32300883
[TBL] [Abstract][Full Text] [Related]
24. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Gerds AT; Gotlib J; Ali H; Bose P; Dunbar A; Elshoury A; George TI; Gundabolu K; Hexner E; Hobbs GS; Jain T; Jamieson C; Kaesberg PR; Kuykendall AT; Madanat Y; McMahon B; Mohan SR; Nadiminti KV; Oh S; Pardanani A; Podoltsev N; Rein L; Salit R; Stein BL; Talpaz M; Vachhani P; Wadleigh M; Wall S; Ward DC; Bergman MA; Hochstetler C
J Natl Compr Canc Netw; 2022 Sep; 20(9):1033-1062. PubMed ID: 36075392
[TBL] [Abstract][Full Text] [Related]
26. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
Tefferi A; Skoda R; Vardiman JW
Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
[TBL] [Abstract][Full Text] [Related]
27. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
[TBL] [Abstract][Full Text] [Related]
28. Biology and Current Treatment of Myeloproliferative Neoplasms.
Ali H; Pullarkat V; Snyder D
Cancer Treat Res; 2021; 181():151-165. PubMed ID: 34626360
[TBL] [Abstract][Full Text] [Related]
29. The roles of sex and genetics in the MPN.
Moliterno AR; Braunstein EM
Int Rev Cell Mol Biol; 2022; 366():1-24. PubMed ID: 35153002
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms.
Schino M; Fiorentino V; Rossi E; Betti S; Di Cecca M; Ranucci V; Chiusolo P; Martini M; De Stefano V; Larocca LM
Haematologica; 2021 Dec; 106(12):3162-3169. PubMed ID: 33543865
[TBL] [Abstract][Full Text] [Related]
31. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
32. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
33. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
34. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
35. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
36. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
37. Approach to MPN Symptom Assessment.
Geyer H; Mesa RA
Curr Hematol Malig Rep; 2017 Oct; 12(5):381-388. PubMed ID: 28942516
[TBL] [Abstract][Full Text] [Related]
38. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Agarwal MB; Malhotra H; Chakrabarti P; Varma N; Mathews V; Bhattacharyya J; Seth T; Gayathri K; Menon H; Subramanian PG; Sharma A; Bhattacharyya M; Mehta J; Vaid AK; Shah S; Aggarwal S; Gogoi PK; Nair R; Agarwal U; Varma S; Prasad SV; Manipadam MT
Indian J Med Paediatr Oncol; 2015; 36(1):3-16. PubMed ID: 25810569
[TBL] [Abstract][Full Text] [Related]
39. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
40. Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool.
Rudzki Z; Kawa R; Okoñ K; Szczygieł E; Stachura J
Virchows Arch; 2006 Jan; 448(1):59-67. PubMed ID: 16220296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]